Sosei Group Corporation has appointed Peter Bains as chief operating officer and chief executive-designate to succeed Shinichi Tamura, the current CEO and company founder. Based in Tokyo, Sosei is a global biopharmaceutical business and owns the UK neurology specialist Heptares Therapeutics. Mr Bains is currently chief executive of Syngene, a service provider, and a non-executive director of Sosei. He previously worked as a consultant and as an executive at GlaxoSmithKline Plc.
Copyright 2016 Evernow Publishing Ltd